ADC Therapeutics SA (ADCT)

USD 1.91

(-10.33%)

Operating Expenses Summary of ADC Therapeutics SA

  • ADC Therapeutics SA's latest annual operating expenses in 2023 was 233.01 Million USD , down -29.17% from previous year.
  • ADC Therapeutics SA's latest quarterly operating expenses in 2024 Q2 was 44.39 Million USD , down -8.11% from previous quarter.
  • ADC Therapeutics SA reported a annual operating expenses of 328.95 Million USD in annual operating expenses 2022, up 11.8% from previous year.
  • ADC Therapeutics SA reported a annual operating expenses of 294.24 Million USD in annual operating expenses 2021, up 34.2% from previous year.
  • ADC Therapeutics SA reported a quarterly operating expenses of 44.39 Million USD for 2024 Q2, down -8.11% from previous quarter.
  • ADC Therapeutics SA reported a quarterly operating expenses of 57.75 Million USD for 2023 Q2, down -17.47% from previous quarter.

Annual Operating Expenses Chart of ADC Therapeutics SA (2023 - 2017)

Historical Annual Operating Expenses of ADC Therapeutics SA (2023 - 2017)

Year Operating Expenses Operating Expenses Growth
2023 233.01 Million USD -29.17%
2022 328.95 Million USD 11.8%
2021 294.24 Million USD 34.2%
2020 219.26 Million USD 80.11%
2019 121.73 Million USD -4.2%
2018 127.08 Million USD 35.95%
2017 93.47 Million USD 0.0%

Peer Operating Expenses Comparison of ADC Therapeutics SA

Name Operating Expenses Operating Expenses Difference
Alto Neuroscience, Inc. 37.8 Million USD -516.295%
Annovis Bio, Inc. 45.03 Million USD -417.409%
Biohaven Pharmaceutical Holding Company Ltd. 436.05 Million USD 46.562%
Ginkgo Bioworks Holdings, Inc. 1.1 Billion USD 78.977%
Nuvation Bio Inc. 99.82 Million USD -133.431%
Nuvation Bio Inc. 99.82 Million USD -133.431%
Arcus Biosciences, Inc. 457 Million USD 49.012%
Theriva Biologics, Inc. 21.43 Million USD -987.28%
Zymeworks Inc. 196.76 Million USD -18.426%